dr. R.H. Enting

No picture available
r.h.enting umcg.nl


  1. 2020
  2. 2019
  3. 2018
  4. Gao, Y., Weenink, B., van den Bent, M. J., Erdem-Eraslan, L., Kros, J. M., Smitt, P. A. E. S., Hoang-Xuan, K., Brandes, A. A., Vos, M., Dhermain, F., Enting, R., Ryan, G. F., Chinot, O., Ben Hassel, M., van Linde, M. E., Mason, W. P., Gijtenbeek, J. M. M., Balana, C., von Deimling, A., ... French, P. J. (2018). Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 94, 168-178. https://doi.org/10.1016/j.ejca.2018.02.023
  5. Bady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang-Xuan, K., Vauleon, E., Gijtenbeek, A., Enting, R., Thiessen, B., Chinot, O., Dhermain, F., Brandes, A. A., Reijneveld, J. C., Marosi, C., Taphoorn, M. J. B., Wick, W., von Deimling, A., French, P., ... Hegi, M. E. (2018). The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 135(4), 601-615. https://doi.org/10.1007/s00401-018-1810-6
  6. 2017
  7. Doorduijn, J. K., van Imhoff, G. W., van der Holt, B., Schouten, H. C., Schaafsma, M. R., MacKenzie, M. A., Baars, J. W., Kersten, M. J., Lugtenburg, P. J., van den Bent, M. J., Enting, R. H., Spoelstra, F. M., Poortmans, P., & Bromberg, J. E. C. (2017). Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: Results of the HOVON 80 phase 2 study. HEMATOLOGICAL ONCOLOGY, 35(4), 497-503. https://doi.org/10.1002/hon.2342
  8. van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., Wheeler, H., Chinot, O. L., Gill, S., Griffin, M., Brachman, D. G., Taal, W., Rudà, R., Weller, M., McBain, C., ... Kros, J. M. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomised, open-label intergroup study. The Lancet, 390(10103), 1645-1653. https://doi.org/10.1016/S0140-6736(17)31442-3
  9. 2016
  10. Reijneveld, J. C., Taphoorn, M. J. B., Coens, C., Bromberg, J. E. C., Mason, W. P., Hoang-Xuan, K., Ryan, G., Ben Hassel, M., Enting, R. H., Brandes, A. A., Wick, A., Chinot, O., Reni, M., Kantor, G., Thiessen, B., Klein, M., Verger, E., Borchers, C., Hau, P., ... Baumert, B. G. (2016). Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1533-1542. https://doi.org/10.1016/S1470-2045(16)30305-9
  11. Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Ben Hassel, M., Hartmann, C., Ryan, G., Capper, D., Kros, J. M., Kurscheid, S., Wick, W., Enting, R., Reni, M., Thiessen, B., ... Stupp, R. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1521-1532. https://doi.org/10.1016/S1470-2045(16)30313-8
  12. van Sonderen, A., Schreurs, M. W. J., de Bruijn, M. A. A. M., Boukhrissi, S., Nagtzaam, M. M. P., Hulsenboom, E. S. P., Enting, R. H., Thijs, R. D., Wirtz, P. W., Smitt, P. A. E. S., & Titulaer, M. J. (2016). The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology, 86(18), 1692-1699. https://doi.org/10.1212/WNL.0000000000002637
  13. Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., Dinjens, W. N. M., Gorlia, T., & van den Bent, M. J. (2016). Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 18(3), 388-400. https://doi.org/10.1093/neuonc/nov182
  14. 2015
  15. Dubbinkl, E., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., Dinjens, W. N., Gorlia, T., & van den Bent, M. J. (2015). Molecular Classification of Anaplastic Oligodendroglioma Using Next-generation Sequencing: A Report of the Prospective Randomized EORTC Brain Tumor Group 26951 Phase III Trial. Journal of molecular diagnostics, 17(6), 818-818.
  16. 2014
  17. Ho, V. K. Y., Reijneveld, J. C., Enting, R., Bienfait, H. P., Robe, P., Baumert, B. G., Visser, O., & Dutch Soc Neuro-Oncology LWNO (2014). Changing incidence and improved survival of gliomas. European Journal of Cancer, 50(13), 2309-2318. https://doi.org/10.1016/j.ejca.2014.05.019
  18. Taal, W., Oosterkamp, H. M., Walenkamp, A. M. E., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C. J., Buter, J., Honkoop, A. H., Boerman, D., de Vos, F. Y. F., Dinjens, W. N. M., Enting, R., Taphoorn, M. J. B., van den Berkmortel, F. W. P. J., Jansen, R. L. H., Brandsma, D., Bromberg, J. E. C., van Heuvel, I., Vernhout, R. M., ... van den Bent, M. J. (2014). Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncology, 15(9), 943-953. https://doi.org/10.1016/S1470-2045(14)70314-6
  19. Habets, E. J. J., Taphoorn, M. J. B., Nederend, S., Klein, M., Delgadillo, D., Hoang-Xuan, K., Bottomley, A., Allgeier, A., Seute, T., Gijtenbeek, A. M. M., de Gans, J., Enting, R., Tijssen, C. C., van den Bent, M. J., & Reijneveld, J. C. (2014). Health-related quality of life and cognitive functioning in longterm anaplastic oligodendroglioma and oligoastrocytoma survivors. JOURNAL OF NEURO-ONCOLOGY, 116(1), 161-168. https://doi.org/10.1007/s11060-013-1278-0
  20. 2013
  21. van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., Enting, R., French, P. J., Dinjens, W. N. M., Vecht, C. J., Allgeier, A., Lacombe, D., Gorlia, T., & Hoang-Xuan, K. (2013). Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology, 31(3), 344-350. https://doi.org/10.1200/JCO.2012.43.2229
  22. 2012
  23. 2011
  24. 2010
  25. Schuurmans, M., Bromberg, J. E. C., Doorduijn, J., Poortmans, P., Taphoorn, M. J. B., Seute, T., Enting, R., van Imhoff, G., van Norden, Y., & van den Bent, M. J. (2010). Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. British Journal of Haematology, 151(2), 179-184. https://doi.org/10.1111/j.1365-2141.2010.08328.x
  26. 2009
  27. Gehring, K., Sitskoorn, M. M., Gundy, C. M., Sikkes, S. A. M., Klein, M., Postma, T. J., van den Bent, M. J., Beute, G. N., Enting, R. H., Kappelle, A. C., Boogerd, W., Veninga, T., Twijnstra, A., Boerman, D. H., Taphoorn, M. J. B., & Aaronson, N. K. (2009). Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. Journal of Clinical Oncology, 27(22), 3712-3722. https://doi.org/10.1200/JCO.2008.20.5765
  28. 2008
  29. 2007
  30. Sillevis Smitt, P. A. E., Polman, S. K. L., de Beukelaar, J. W. K., Enting, R. H., van den Bent, M. J., Bromberg, J. E., Kros, J. M., & Hooijkaas, H. (2007). Drie patiënten met een paraneoplastisch neurologisch syndroom; de betekenis van paraneoplastische antistoffen. Nederlands Tijdschrift voor Geneeskunde, 151(15), 874-880.
  31. 2006
  32. 2005
  33. Taal, W., van der Rijt, C. D. D., Sillevis Smitt, P. A. E., Kros, J. M., van Heuvel, I., Enting, R. H., & van den Bent, M. J. (2005). Gunstig resultaat van temozolomide bij een recidiefvan een hooggradig glioom. Nederlands Tijdschrift voor Geneeskunde, 149(25), 1393-1399.
  34. Stege, E. M. B., Kros, J. M., de Bruin, H. G., Enting, R. H., van Heuvel, I., Looijenga, L. H. J., van der Rijt, C. D. D., Smitt, P. A. E. S., & van den Bent, M. J. (2005). Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 103(4), 802-809. https://doi.org/10.1002/cncr.20828
  35. Enting, R., Mucchiano, C., Oldenmenger, WH., Fritzon, M., Wallen, A., Goslinga-van der Gaag, S., Smitt, PAES., & Delhaas, E. (2005). The "pain pen" for breakthrough cancer pain: A promising treatment. Journal of Pain and Symptom Management, 29(2), 213-217. https://doi.org/10.1016/j.jpainsymman.2004.05.010
  36. 2004
  37. Triebels, V. H. J. M., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Frenay, M., Tosoni, A., Kros, J. M., Biemond-ter Stege, E., Enting, R. H., Allgeier, A., van Heuvel, I., & van den Bent, M. J. (2004). Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology, 63(5), 904-906. https://doi.org/10.​1212/​01.​WNL.​0000137049.​65631.​DB
  38. ten Tije, A. J., Loos, W. J., Zhao, M., Baker, S. D., Enting, R. H., van der Meulen, H., Verweij, J., & Sparreboom, A. (2004). Limited cerebrospinal fluid penetration of docetaxel. Anti-Cancer Drugs, 15(7), 715-718.
  39. 2002
  40. Enting, R. H., Oldenmenger, W. H., van der Rijt, C. C. D., Wilms, E. B., Elfrink, E. J., Elswijk, I., & Sillevis Smitt, P. A. E. (2002). A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer, 94(11), 3049-3056. https://doi.org/10.1002/cncr.10518
  41. Enting, R. H., Oldenmenger, W. H., van der Rijt, C. CD., Koper, P., Lieverse, P. J., & Smitt Sillevis, P. AE. (2002). Nitrous oxide is not beneficial for breakthrough cancer pain. Palliative Medicine, 16(3), 257-259. https://doi.org/10.1191/0269216302pm546xx
  42. 2001
Previous 1 2 Next

ID: 17564626